VXRT inventory forecast 2025 refers back to the predicted efficiency of the inventory of Vaxart, Inc. (VXRT) within the yr 2025. Inventory forecasts try to predict the long run value of a inventory based mostly on varied components reminiscent of the corporate’s monetary efficiency, trade tendencies, and total financial circumstances.
VXRT is a clinical-stage biotechnology firm centered on creating oral vaccines for infectious illnesses. The corporate’s lead product candidate is VXA-CoV2-1, an oral vaccine for COVID-19. Vaxart has additionally developed oral vaccines for norovirus, seasonal influenza, and respiratory syncytial virus (RSV).
